FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2501030153> ?p ?o ?g. }

• W2501030153 abstract "Abstract INTRODUCTION: Treatment for acute myeloid leukemia (AML) presents a significant economic burden to patients, health care insurers and society, and is expected to remain so in the near future. There are few studies describing the costs of AML in the literature. However, the high cost of treating AML and the demographic evolution of the world population, indicate that such studies are needed to support ongoing efforts to allocate resources efficiently in health care. OBJECTIVE: To describe and compare the costs of AML therapies daily used at the Antwerp University Hospital in adult patients receiving chemotherapy with/without stem cell transplantation and in patients receiving immunotherapy using dendritic cell vaccination. DESIGN AND METHODS: This monocentric study compares direct hospital medical costs of treatment for AML between 2005 and 2010, allocated and charged according to the hospital analytic accounting system. Information on use of medical resources was collected from electronic medical records. Professional and facility charges associated with inpatient and outpatient management were collected using electronic billing information. Drug costs and drug administration costs were based on list prices published by the Belgian reimbursement authority (RIZIV/INAMI). The cost analysis distinguished between group 1, patients treated with induction and consolidation therapy alone; group 2, patients treated with induction and consolidation therapy plus allogeneic hematopoietic stem cell transplantation (HSCT) and group 3, patients treated with induction and consolidation therapy plus immunotherapy using dendritic cells engineered to express the Wilms’ tumor protein (Van Tendeloo et al. Proc Natl Acad Sci USA. 2010;107(31):13824-9). RESULTS AND DISCUSSION: 51 adult patients who were treated for newly diagnosed AML were included. Costs on medical and nursing care at the hematology ward, pharmaceutical prescriptions, transfer episodes to the intensive care ward, laboratory tests and medical imaging were analyzed. The cost of dendritic cell vaccine preparation was € 20 450 per patient. The median cost in group 1 (15 patients) was € 32,648 (range: € 4,759 - € 140,383). Only 1 patient in group 1 went into remission after induction therapy and received consolidation therapy. All patients in group 1 died within 5 year after diagnosis, 13 patients died within 1 year and 5 died within 1 month. The median cost in group 2 (26 patients) was € 184,554 (range: € 87,932 - € 449,155). The median post-consolidation treatment cost in group 2 was € 110,430 (range: € 31,364 - € 255,948). Five-year survival in group 2 was 19%. Seventeen patients in group 2 died within 1 year after HSCT. The median cost in group 3 (10 patients) was € 88,635 (range: € 23,392 - € 215,119). The median post-consolidation treatment cost in group 3 was € 40,748 (range: € 26,907- € 156,870). Five-year survival in group 3 was 30%. Four patients in group 3 died within 1 year after vaccination. CONCLUSION: This study comparing different post-consolidation therapies confirmes the high cost of treating AML and suggests that savings to the healthcare system could be achieved by sustaining complete remission status for longer periods. Dendritic cell vaccination is one of the new therapeutic options to attain a long remission status. Disclosures No relevant conflicts of interest to declare." @default.
• W2501030153 created "2016-08-23" @default.
• W2501030153 creator A5010168843 @default.
• W2501030153 creator A5015223856 @default.
• W2501030153 creator A5018700375 @default.
• W2501030153 creator A5023091698 @default.
• W2501030153 creator A5028297614 @default.
• W2501030153 creator A5028646034 @default.
• W2501030153 creator A5029919732 @default.
• W2501030153 creator A5039137453 @default.
• W2501030153 creator A5059585157 @default.
• W2501030153 creator A5063714660 @default.
• W2501030153 creator A5071493867 @default.
• W2501030153 creator A5076138054 @default.
• W2501030153 date "2014-12-06" @default.
• W2501030153 modified "2023-09-30" @default.
• W2501030153 title "Cost Analysis of Immunotherapy Using Dendritic Cells for Acute Myeloid Leukemia Patients" @default.
• W2501030153 doi "https://doi.org/10.1182/blood.v124.21.1322.1322" @default.
• W2501030153 hasPublicationYear "2014" @default.
• W2501030153 type Work @default.
• W2501030153 sameAs 2501030153 @default.
• W2501030153 citedByCount "2" @default.
• W2501030153 countsByYear W25010301532019 @default.
• W2501030153 countsByYear W25010301532020 @default.
• W2501030153 crossrefType "journal-article" @default.
• W2501030153 hasAuthorship W2501030153A5010168843 @default.
• W2501030153 hasAuthorship W2501030153A5015223856 @default.
• W2501030153 hasAuthorship W2501030153A5018700375 @default.
• W2501030153 hasAuthorship W2501030153A5023091698 @default.
• W2501030153 hasAuthorship W2501030153A5028297614 @default.
• W2501030153 hasAuthorship W2501030153A5028646034 @default.
• W2501030153 hasAuthorship W2501030153A5029919732 @default.
• W2501030153 hasAuthorship W2501030153A5039137453 @default.
• W2501030153 hasAuthorship W2501030153A5059585157 @default.
• W2501030153 hasAuthorship W2501030153A5063714660 @default.
• W2501030153 hasAuthorship W2501030153A5071493867 @default.
• W2501030153 hasAuthorship W2501030153A5076138054 @default.
• W2501030153 hasConcept C121608353 @default.
• W2501030153 hasConcept C126322002 @default.
• W2501030153 hasConcept C143998085 @default.
• W2501030153 hasConcept C160735492 @default.
• W2501030153 hasConcept C162324750 @default.
• W2501030153 hasConcept C2777408962 @default.
• W2501030153 hasConcept C2777701055 @default.
• W2501030153 hasConcept C2778729363 @default.
• W2501030153 hasConcept C2779703844 @default.
• W2501030153 hasConcept C2908647359 @default.
• W2501030153 hasConcept C2911091166 @default.
• W2501030153 hasConcept C50522688 @default.
• W2501030153 hasConcept C71924100 @default.
• W2501030153 hasConcept C99454951 @default.
• W2501030153 hasConceptScore W2501030153C121608353 @default.
• W2501030153 hasConceptScore W2501030153C126322002 @default.
• W2501030153 hasConceptScore W2501030153C143998085 @default.
• W2501030153 hasConceptScore W2501030153C160735492 @default.
• W2501030153 hasConceptScore W2501030153C162324750 @default.
• W2501030153 hasConceptScore W2501030153C2777408962 @default.
• W2501030153 hasConceptScore W2501030153C2777701055 @default.
• W2501030153 hasConceptScore W2501030153C2778729363 @default.
• W2501030153 hasConceptScore W2501030153C2779703844 @default.
• W2501030153 hasConceptScore W2501030153C2908647359 @default.
• W2501030153 hasConceptScore W2501030153C2911091166 @default.
• W2501030153 hasConceptScore W2501030153C50522688 @default.
• W2501030153 hasConceptScore W2501030153C71924100 @default.
• W2501030153 hasConceptScore W2501030153C99454951 @default.
• W2501030153 hasLocation W25010301531 @default.
• W2501030153 hasOpenAccess W2501030153 @default.
• W2501030153 hasPrimaryLocation W25010301531 @default.
• W2501030153 hasRelatedWork W2104222465 @default.
• W2501030153 hasRelatedWork W2146549434 @default.
• W2501030153 hasRelatedWork W2341931364 @default.
• W2501030153 hasRelatedWork W2562235864 @default.
• W2501030153 hasRelatedWork W2584802404 @default.
• W2501030153 hasRelatedWork W2595008430 @default.
• W2501030153 hasRelatedWork W2595655574 @default.
• W2501030153 hasRelatedWork W2611278239 @default.
• W2501030153 hasRelatedWork W2920959584 @default.
• W2501030153 hasRelatedWork W2923618001 @default.
• W2501030153 hasRelatedWork W2951183717 @default.
• W2501030153 hasRelatedWork W2972915484 @default.
• W2501030153 hasRelatedWork W2977442888 @default.
• W2501030153 hasRelatedWork W2979441907 @default.
• W2501030153 hasRelatedWork W2980152564 @default.
• W2501030153 hasRelatedWork W2985725314 @default.
• W2501030153 hasRelatedWork W2987213589 @default.
• W2501030153 hasRelatedWork W3007168322 @default.
• W2501030153 hasRelatedWork W3019914276 @default.
• W2501030153 hasRelatedWork W3077284673 @default.
• W2501030153 isParatext "false" @default.
• W2501030153 isRetracted "false" @default.
• W2501030153 magId "2501030153" @default.
• W2501030153 workType "article" @default.